Developer docs
API playgroundTry for free, no card

Search company profiles

Transformation Capital

Full company profile

uuid000024n

Namestring
Transformation Capital
Legal namestring
Transformation Capital Partners, L.P.
Company typeenum
Private
Founded yearint
2019
Descriptiontext

Transformation Capital is a Boston-headquartered, healthcare-specialist growth equity and venture capital firm that provides capital, strategic guidance, and industry network access exclusively to digital health, health IT, and healthcare services companies. The firm, operating as Transformation Capital Partners, L.P. (with related advisory entity Transformation Capital Advisers), was founded circa 2017-2019 and is led by co-founder and managing partner Todd Cozzens alongside managing partners Jared Kesselheim, M.D. and Mike Dixon. It maintains a 24-person team split across an 11-member Investment Team, a 5-member Partner Acceleration Team that supports portfolio company operating priorities, and an 8-member Operations Team.

The firm has built a portfolio of more than 30 active and exited healthcare companies spanning virtual care (Sword Health, Grow Therapy, PlushCare), pharmacy benefit management (Capital Rx/Judi Health), clinical AI (Latent, Qualified Health, Alaffia Health, SmarterDx), life sciences compliance (Ketryx), data infrastructure (Datavant), practice technology (Tebra, Parachute Health), and value-based care (Groups Recover Together, Mosaic Health, Local Infusion). Notable outcomes include Sword Health reaching a $3B valuation, Grow Therapy reaching $3B valuation with over $1B in annual revenue, and exits via Health Catalyst IPO, SmarterDx (NMC acquisition), and Scientist.com (GHO Capital acquisition).

The business model follows standard private fund economics: Transformation Capital raises capital from institutional limited partners into privately offered funds (Transformation Capital Funds) and earns revenue through management fees on committed/invested capital plus carried interest on fund returns. Investment terms are negotiated privately via private placement memoranda and are not publicly disclosed. The firm's go-to-market is relationship-driven and healthcare-specific, relying on direct founder outreach, warm introductions from existing portfolio CEOs, healthcare executive referrals, and content marketing (Perspectives blog, Accelerating Impact newsletter) rather than mass-market channels.

Short descriptiontext

Boston-based healthcare-specialist growth equity firm providing capital and strategic guidance exclusively to digital health startups, managing a 30+ company portfolio with a 24-person team and exits including Health Catalyst IPO and SmarterDx.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBoston, United States
HQ citystring
Boston
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
healthcare growth equity, digital health venture capital, healthcare IT investing, growth-stage healthcare funds, healthcare startup investment
Industry2 codes
1Healthcare & Life Sciences Growth Equity
CodeFSANACABPrimaryYes
2Technology & Software Growth Equity
CodeFSANACAAPrimaryNo
NAICS code3 codes
  • Portfolio Management and Investment Advice523940
  • Portfolio Management and Investment Advice52394
  • Other Financial Vehicles525990
SIC code1 code
  • Investment Advice6282
Product category
Healthcare Venture Capital / Growth Equity
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Venture capital fund management
TypeManaged Services
Description

Transformation Capital Partners, L.P. operates as a private investment advisor managing capital pools ("Transformation Capital Funds") on behalf of limited partners. Revenue is generated through typical private fund economics: management fees on committed/invested capital and carried interest (carried interest/profit participation) on fund returns. The firm explicitly states it provides investment advisory services only to privately offered funds and does not solicit services to the public.

transformcap.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure, Others
Pricing details1 tier
1Private fund vehicles — pricing/terms not publicly disclosed
ModelOtherBilling cadenceMulti-year contract
Notes

Investment terms negotiated privately with limited partners; not publicly disclosed.

transformcap.com
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Transformation Capital is a healthcare-focused growth equity firm that invests exclusively in digital health, health IT, and healthcare services companies from Series A through growth stages. The firm provides capital from privately offered investment funds advised by Transformation Capital Advisers, combined with sector-specific strategic guidance, board-level involvement, and curated introductions to healthcare leaders across payers, providers, and health systems.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 10 values shown
  • Portfolio impact: Sword Health achieved 3B valuation across multiple funding rounds including $130M raise at $3B valuation in June 2024
+9 more records
Product overview1 text field

Transformation Capital is a digital healthcare-focused venture capital investment firm rather than a software product company; its offering is growth-stage equity capital and strategic partnership support exclusively to healthcare companies. The firm does not maintain its own branded technology products, modules, or platforms — its website (transformcap.com) functions purely as informational, marketing, and investor-relations content, while operational services are delivered via a non-public limited-partner portal (InvestranDX). The publicly visible "offerings" are therefore its investment services and the curated portfolio of partner companies (e.g., Sword Health, Datavant, Grow Therapy, Capital Rx/Judi Health, Tebra, Alaffia, Latent, Qualified Health, Ketryx, SmarterDx, CodaMetrix, Parachute Health, Rad AI, Local Infusion, Solstice Health), with no unified in-house product platform binding them.

Product and service2 records
1Transformation Capital Funds (Privately Offered Investment Funds)
CategoryVenture capital fund vehicles / private investment funds
Description

Privately offered venture capital funds that invest exclusively in digital health, health IT, and healthcare services companies from Series A through growth stages. The funds are advised by Transformation Capital Advisers and accessed by limited partners via the InvestranDX limited partners portal.

2Growth-Stage Equity Investment Services
CategoryHealthcare venture capital advisory services
Description

Investment advisory services for healthcare startup founders and management teams, providing growth-stage equity capital combined with board-level involvement, sector-specific strategic guidance, and curated introductions to healthcare leaders across payers, providers, and health systems. Founders initiate contact via [email protected].

Scale indicator12 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierFlagshipTypeStrategic or Co-development Partner
Description

Transformation Capital's network of healthcare leaders is a core strategic asset. The firm explicitly states: 'Knowing who's who in healthcare matters. We help our partner companies connect to the right people at the right time for the right solution to drive forward progress.' This network serves as a referral and commercial-introduction channel for portfolio companies to accelerate customer acquisition and partnership formation.

2Healthcare founders and entrepreneurs
Strategic tierFlagshipTypeStrategic or Co-development Partner
Description

TC partners 'in tandem with our partners and see their success as our success' — providing not just capital but 'proven experience they can benefit from, AND a network of healthcare leaders who can use their innovations to help transform the industry and provide feedback for continuous improvement.' This bidirectional relationship differentiates TC from typical financial-only VCs.

transformcap.com
Recent move18 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Healthcare- and fintech-dedicated growth equity firm with a similar investment stage focus (Series A through growth) and a deep operating-partner model. Directly comparable as a thesis-driven, sector-specialist growth investor backing digital health and healthcare services companies.

TypeDirect peer
Description

Boston-based venture capital firm exclusively focused on healthcare technology and services. Frequently co-invests with TC (e.g., Qualified Health's $125M Series B), sharing a similar early-to-growth stage focus on digital health and provider/payer enablement.

TypeDirect peer
Description

Healthcare-focused venture capital firm investing across early- and growth-stage digital health, services, and technology companies. Frequently co-invests alongside TC (Qualified Health Series B), with comparable sector specialization and portfolio support model.

TypeDirect peer
Description

Healthcare-dedicated venture firm focused on companies transforming care for underserved and complex populations. Co-invested with TC in Qualified Health's $125M Series B and shares a similar thesis-driven, healthcare-only investment approach.

TypeBroad incumbent
Description

Large multi-stage venture firm with one of the most prominent dedicated healthcare practices (Health Assurance). Co-invested with TC in Latent's $80M Series A and pursues similar digital health, payer/provider, and AI-enabled healthcare themes at typically larger fund and check sizes.

TypeBroad incumbent
Description

One of the largest venture firms with a longstanding healthcare practice. Led Qualified Health's $125M Series B in which TC participated, and overlaps with TC across digital health, payer technology, and provider enablement themes at scale.

TypeBroad incumbent
Description

Large venture firm with a dedicated Bio + Health fund actively investing across digital health, healthcare AI, and care delivery. Competitor for healthcare AI deals and broader digital health rounds, though it operates at materially larger fund and check sizes than TC.

TypeDirect peer
Description

Long-tenured venture firm with a deep healthcare practice covering digital health, therapeutics, and diagnostics. Comparable as a thesis-driven healthcare investor with similar early-to-growth stage focus and a track record of healthcare exits.

TypeDirect peer
Description

Strategic healthcare venture platform formed by Cambia Health Solutions and Mosaic Health Solutions. Invests across digital health and care delivery with a payer-aligned approach that mirrors TC's emphasis on payer/provider network leverage.

TypeBroad incumbent
Description

Large multi-stage venture firm with a dedicated healthcare practice covering digital health, tech-enabled services, and biotech. Overlaps with TC across growth-stage digital health and AI-enabled care delivery themes, typically writing larger checks.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers15 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment74 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Transformation Capital

Healthcare Venture Capital / Growth Equitytransformcap.com

Boston-based healthcare-specialist growth equity firm providing capital and strategic guidance exclusively to digital health startups, managing a 30+ company portfolio with a 24-person team and exits including Health Catalyst IPO and SmarterDx.

What Transformation Capital does

Transformation Capital is a Boston-headquartered, healthcare-specialist growth equity and venture capital firm that provides capital, strategic guidance, and industry network access exclusively to digital health, health IT, and healthcare services companies. The firm, operating as Transformation Capital Partners, L.P. (with related advisory entity Transformation Capital Advisers), was founded circa 2017-2019 and is led by co-founder and managing partner Todd Cozzens alongside managing partners Jared Kesselheim, M.D. and Mike Dixon. It maintains a 24-person team split across an 11-member Investment Team, a 5-member Partner Acceleration Team that supports portfolio company operating priorities, and an 8-member Operations Team.

The firm has built a portfolio of more than 30 active and exited healthcare companies spanning virtual care (Sword Health, Grow Therapy, PlushCare), pharmacy benefit management (Capital Rx/Judi Health), clinical AI (Latent, Qualified Health, Alaffia Health, SmarterDx), life sciences compliance (Ketryx), data infrastructure (Datavant), practice technology (Tebra, Parachute Health), and value-based care (Groups Recover Together, Mosaic Health, Local Infusion). Notable outcomes include Sword Health reaching a $3B valuation, Grow Therapy reaching $3B valuation with over $1B in annual revenue, and exits via Health Catalyst IPO, SmarterDx (NMC acquisition), and Scientist.com (GHO Capital acquisition).

The business model follows standard private fund economics: Transformation Capital raises capital from institutional limited partners into privately offered funds (Transformation Capital Funds) and earns revenue through management fees on committed/invested capital plus carried interest on fund returns. Investment terms are negotiated privately via private placement memoranda and are not publicly disclosed. The firm's go-to-market is relationship-driven and healthcare-specific, relying on direct founder outreach, warm introductions from existing portfolio CEOs, healthcare executive referrals, and content marketing (Perspectives blog, Accelerating Impact newsletter) rather than mass-market channels.

Transformation Capital firmographics

Firmographics
Name
Transformation Capital
Legal name
Transformation Capital Partners, L.P.
Website
https://transformcap.com
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
11–50 employees
Short description
Boston-based healthcare-specialist growth equity firm providing capital and strategic guidance exclusively to digital health startups, managing a 30+ company portfolio with a 24-person team and exits including Health Catalyst IPO and SmarterDx.
Ownership category
akta.pro rank

Transformation Capital industry classification

Industry
Product category
Healthcare Venture Capital / Growth Equity
NAICS
Portfolio Management and Investment Advice (523940), Portfolio Management and Investment Advice (52394), Other Financial Vehicles (525990)
SIC
Investment Advice (6282)
akta.pro primary industry
Healthcare & Life Sciences Growth Equity (FSANACAB)
akta.pro secondary industry
Technology & Software Growth Equity (FSANACAA)

Keywords

  • Healthcare growth equity
  • Digital health venture capital
  • Healthcare IT investing
  • Growth-stage healthcare funds
  • Healthcare startup investment

Where Transformation Capital is headquartered

Location

Headquarters

HQ city
Boston
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Transformation Capital business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure, Others

Revenue model

  1. Venture capital fund management: Transformation Capital Partners, L.P. operates as a private investment advisor managing capital pools ("Transformation Capital Funds") on behalf of limited partners. Revenue is generated through typical private fund economics: management fees on committed/invested capital and carried interest (carried interest/profit participation) on fund returns. The firm explicitly states it provides investment advisory services only to privately offered funds and does not solicit services to the public.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractPrivate fund vehicles — pricing/terms not publicly disclosed

Go-to-market motion2 records

Distribution channels2 records

Marketing channels7 records

Transformation Capital product offering

Product offering

Core offering

Transformation Capital is a healthcare-focused growth equity firm that invests exclusively in digital health, health IT, and healthcare services companies from Series A through growth stages. The firm provides capital from privately offered investment funds advised by Transformation Capital Advisers, combined with sector-specific strategic guidance, board-level involvement, and curated introductions to healthcare leaders across payers, providers, and health systems.

Product overview

Transformation Capital is a digital healthcare-focused venture capital investment firm rather than a software product company; its offering is growth-stage equity capital and strategic partnership support exclusively to healthcare companies. The firm does not maintain its own branded technology products, modules, or platforms — its website (transformcap.com) functions purely as informational, marketing, and investor-relations content, while operational services are delivered via a non-public limited-partner portal (InvestranDX). The publicly visible "offerings" are therefore its investment services and the curated portfolio of partner companies (e.g., Sword Health, Datavant, Grow Therapy, Capital Rx/Judi Health, Tebra, Alaffia, Latent, Qualified Health, Ketryx, SmarterDx, CodaMetrix, Parachute Health, Rad AI, Local Infusion, Solstice Health), with no unified in-house product platform binding them.

Differentiator

Problem solved

Functional benefit

Products and services

  • Transformation Capital Funds (Privately Offered Investment Funds) Privately offered venture capital funds that invest exclusively in digital health, health IT, and healthcare services companies from Series A through growth stages. The funds are advised by Transformation Capital Advisers and accessed by limited partners via the InvestranDX limited partners portal.
  • Growth-Stage Equity Investment Services Investment advisory services for healthcare startup founders and management teams, providing growth-stage equity capital combined with board-level involvement, sector-specific strategic guidance, and curated introductions to healthcare leaders across payers, providers, and health systems. Founders initiate contact via [email protected].

Quantifiable outcome

  • Portfolio impact: Sword Health achieved 3B valuation across multiple funding rounds including $130M raise at $3B valuation in June 2024
  • +9 more outcomes

Companies that use Transformation Capital

Customer profile

Named customers15 records

Segments3 records

Ideal customer profiles2 records

Transformation Capital technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Transformation Capital partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered flagship.

  • Healthcare industry leaders (executives, payers, providers, health systems)flagshipStrategic or Co-development PartnerTransformation Capital's network of healthcare leaders is a core strategic asset. The firm explicitly states: 'Knowing who's who in healthcare matters. We help our partner companies connect to the right people at the right time for the right solution to drive forward progress.' This network serves as a referral and commercial-introduction channel for portfolio companies to accelerate customer acquisition and partnership formation.
  • Healthcare founders and entrepreneursflagshipStrategic or Co-development PartnerTC partners 'in tandem with our partners and see their success as our success' — providing not just capital but 'proven experience they can benefit from, AND a network of healthcare leaders who can use their innovations to help transform the industry and provide feedback for continuous improvement.' This bidirectional relationship differentiates TC from typical financial-only VCs.

Scale indicators12 records

Recent moves18 records

Expansion highlights4 records

Transformation Capital competitors and assessment

Company assessment

Direct peers

  • Oak HC/FT: Healthcare- and fintech-dedicated growth equity firm with a similar investment stage focus (Series A through growth) and a deep operating-partner model. Directly comparable as a thesis-driven, sector-specialist growth investor backing digital health and healthcare services companies.
  • Flare Capital Partners: Boston-based venture capital firm exclusively focused on healthcare technology and services. Frequently co-invests with TC (e.g., Qualified Health's $125M Series B), sharing a similar early-to-growth stage focus on digital health and provider/payer enablement.
  • Frist Cressey Ventures: Healthcare-focused venture capital firm investing across early- and growth-stage digital health, services, and technology companies. Frequently co-invests alongside TC (Qualified Health Series B), with comparable sector specialization and portfolio support model.
  • Town Hall Ventures: Healthcare-dedicated venture firm focused on companies transforming care for underserved and complex populations. Co-invested with TC in Qualified Health's $125M Series B and shares a similar thesis-driven, healthcare-only investment approach.
  • Venrock: Long-tenured venture firm with a deep healthcare practice covering digital health, therapeutics, and diagnostics. Comparable as a thesis-driven healthcare investor with similar early-to-growth stage focus and a track record of healthcare exits.
  • Echo Health Ventures: Strategic healthcare venture platform formed by Cambia Health Solutions and Mosaic Health Solutions. Invests across digital health and care delivery with a payer-aligned approach that mirrors TC's emphasis on payer/provider network leverage.

Broad incumbents

  • General Catalyst: Large multi-stage venture firm with one of the most prominent dedicated healthcare practices (Health Assurance). Co-invested with TC in Latent's $80M Series A and pursues similar digital health, payer/provider, and AI-enabled healthcare themes at typically larger fund and check sizes.
  • New Enterprise Associates (NEA): One of the largest venture firms with a longstanding healthcare practice. Led Qualified Health's $125M Series B in which TC participated, and overlaps with TC across digital health, payer technology, and provider enablement themes at scale.
  • Andreessen Horowitz (a16z Bio + Health): Large venture firm with a dedicated Bio + Health fund actively investing across digital health, healthcare AI, and care delivery. Competitor for healthcare AI deals and broader digital health rounds, though it operates at materially larger fund and check sizes than TC.
  • Bessemer Venture Partners: Large multi-stage venture firm with a dedicated healthcare practice covering digital health, tech-enabled services, and biotech. Overlaps with TC across growth-stage digital health and AI-enabled care delivery themes, typically writing larger checks.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Transformation Capital social profiles

Digital presence

Transformation Capital compliance and trust

Trust signal

Compliance3 records

Transformation Capital financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Transformation Capital leadership team

Management profile

Number of profiles

Profiles9 records

Transformation Capital funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Transformation Capital M&A and investment

M&A and investment

M&A

Investments74 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Transformation Capital

What does Transformation Capital do?

Transformation Capital is a healthcare-focused growth equity firm that invests exclusively in digital health, health IT, and healthcare services companies from Series A through growth stages. The firm provides capital from privately offered investment funds advised by Transformation Capital Advisers, combined with sector-specific strategic guidance, board-level involvement, and curated introductions to healthcare leaders across payers, providers, and health systems.

Is Transformation Capital a public or private company?

Transformation Capital is a private company. It is classified as management employee owned and is currently operating.

When was Transformation Capital founded?

Transformation Capital was founded in 2019. It employs 11 to 50 people.

Where is Transformation Capital based?

Transformation Capital is headquartered in Boston, United States, in the North America region.

How does Transformation Capital make money?

One revenue line is on record: venture capital fund management.

Who are Transformation Capital's main competitors?

Direct peers on record are Oak HC/FT, Flare Capital Partners, Frist Cressey Ventures, Town Hall Ventures, Venrock and Echo Health Ventures. Broad incumbents are General Catalyst, New Enterprise Associates (NEA), Andreessen Horowitz (a16z Bio + Health) and Bessemer Venture Partners.

Does Transformation Capital have an API?

No public API is recorded for Transformation Capital.

What industry is Transformation Capital in?

Transformation Capital's product category is Healthcare Venture Capital / Growth Equity. Its primary akta.pro industry code is FSANACAB, Healthcare & Life Sciences Growth Equity, with a secondary code of FSANACAA, Technology & Software Growth Equity. Its NAICS code is 523940 and its SIC code is 6282.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Pulse 2.0Transformation Capital Closes $850 Million Fund IV To Back AI-Driven Digital Health CompaniesTransformation Capital closed its fourth fund at an $850 million hard cap, exceeding its target. The healthcare-focused firm will deploy capital into AI-driven digital health companies, increasing its AUM to over $2.5 billion. It has made eight new AI-focused investments in the past year.BostonGlobe.comCan the Institute for Responsible Superintelligence save us from rogue AI?The Institute for Responsible Superintelligence (RESI) was launched in Cambridge to develop mathematical principles for AI safety, aiming to prevent rogue AI actions. Its founders argue that slowing development is insufficient and that safety must be built into design, citing past failures. The nonprofit expects its recommendations to be adopted by AI firms or required by law.Pulse 2.0Latent Expands AI Pharmacy Platform To 60 Health Systems Serving 70 Million PatientsLatent expanded its pharmacy intelligence platform to 60 U.S. health systems serving 70 million patients, adding autonomous clinical agents for medication access. The company is on pace to process over 5.8 million patient medication cases in 12 months, targeting GLP-1 and specialty therapies.citybizTransformation Capital Closes $850 Million Fund IV for Digital Health InvestmentsTransformation Capital closed its fourth fund at an $850 million hard cap, exceeding its target. The Boston- and San Francisco-based firm's total assets under management now exceed $2.5 billion across four funds. It will focus on commercial-stage digital health and AI companies addressing healthcare inefficiencies.Business Wire BlogTransformation Capital Closes Fund IV at $850 Million, Exceeding its Target in Oversubscribed FundraiseTransformation Capital closed Fund IV at $850 million, exceeding its target in an oversubscribed fundraise. The fund brings the firm's total assets under management to over $2.5 billion across four funds. Capital is already being deployed into new partner companies.Venture Capital Access OnlineTransformation Capital Closes Fund IV at $850 Million, Exceeding its Target in Oversubscribed FundraiseTransformation Capital closed Fund IV at $850 million, exceeding its target in an oversubscribed fundraise. The fund brings total assets under management to over $2.5 billion across four funds. Capital is being deployed into new partner companies.VC News DailySolstice Secures $21M Series A FinancingSolstice, an AI-native marketing agency for pharma, raised $21 million in Series A funding led by Transformation Capital, with participation from Twelve Below, Virtue Ventures, and others. The round brings total funding to approximately $25 million, which will fuel go-to-market expansion, product development, and team growth.Pulse 2.0Solstice: $21 Million Series A Raised To Accelerate Pharma CommercializationSolstice, an AI-native marketing agency focused on accelerating pharmaceutical commercialization, announced it raised $21 million in Series A funding led by Transformation Capital, with participation from Twelve Below, Virtue Ventures, and others, bringing total funding to approximately $25 million. The capital will support go-to-market expansion, product development, and team growth across product and customer-facing functions. The company claims customers can launch marketing campaigns 12 times faster than traditional agencies, with content moving from concept to market-ready in roughly 10 days, and now serves more than a dozen pharmaceutical companies including several top 20 pharma brands.HIT ConsultantSolstice Secures $21M for AI-Native Pharmaceutical Marketing PlatformSolstice, an AI-native pharmaceutical marketing platform, announced a $21M Series A funding round led by Transformation Capital, with participation from Twelve Below and Virtue Ventures, bringing total funding to approximately $25M. The platform compresses traditional pharmaceutical marketing asset delivery cycles from three months to 10 days by pairing generative AI algorithms with in-house medical experts, reducing average MLR review cycles from 3.2 rounds to 1.2 rounds per asset and enabling 12x faster campaign launches. The company now serves over a dozen pharmaceutical organizations, including multiple top-20 global pharma brands across oncology, immunology, and metabolic diseases.Tech Funding NewsAI-native pharma marketing startup Solstice raises $21M to cut drug campaign timelines from 3 months to 10 days — TFNSolstice, a New York-based AI-native pharma marketing startup, raised $21 million in Series A funding led by Transformation Capital, bringing total funding to approximately $25 million. The startup's platform reduces pharmaceutical marketing and regulatory review timelines from three months to roughly 10 days, enabling brands to move from content creation to MLR submission in under 48 hours, and already serves over a dozen pharmaceutical companies including several top 20 global pharma brands. The company plans to use the funding to expand go-to-market operations, accelerate product development, and grow engineering and customer-facing teams.